TLDR JAK inhibitors effectively regrow hair in children with alopecia areata and are safe to use.
The document reviews 11 clinical trials with over 5,000 participants, assessing the efficacy and safety of JAK inhibitors for treating pediatric and adolescent alopecia areata. The trials showed that 17–31% of adolescents and 20–40% of mixed-age groups achieved significant hair regrowth by Week 24, outperforming placebo. Most responders maintained regrowth through Week 48. Common side effects included headache, nasopharyngitis/URTI, and acne, with serious adverse events being rare. The study concludes that JAK inhibitors are a promising treatment for pediatric AA, offering durable hair regrowth and a manageable safety profile, better than traditional therapies.
1 citations
,
January 2023 in “Przegląd Dermatologiczny” The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.
12 citations
,
June 2023 in “JAMA network open” JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
3 citations
,
May 2023 in “Clinical drug investigation” JAK inhibitors for alopecia areata are linked to minor side effects like headache and acne, but not to an increased risk of serious adverse events.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
